Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities
Cancer Biome and Targeted Therapy · 14.11.2026 · 252-278
DOI: 10.66505/cbtt.v1i4.56 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biome and Targeted Therapy, online erschienen am 14.11.2026. Verfasst von Piaoting Fu und 3 weiteren Autor:innen. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Changes in metabolism and chromatin regulation help cancer cells sustain proliferation under nutrient limitation and adapt to therapy. Acetyl-CoA and S-adenosylmethionine donate acetyl and methyl groups for histone acetylation and methylation, respectively. Other chromatin-modifying reactions require α-ketoglutarate or NAD⁺, and lactate metabolism contributes to histone lactylation. Regulation also runs in the opposite direction. DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs influence metabolic pathway use by altering expression of enzymes and transporters. These reciprocal effects can stabilize malignant cell states or alter lineage identity and substrate use, with consequences for antitumor immunity, metastatic adaptation, and drug tolerance. Accumulation of 2-hydroxyglutarate, succinate, or fumarate illustrates how metabolic perturbations can directly affect chromatin regulation and cell fate. Studies outside cancer show that some chromatin changes persist after the initiating metabolic stimulus ends. In residual disease, the question is whether cells that retain these changes after drug withdrawal respond differently to subsequent treatment than cells whose chromatin state returns to baseline. The distinction matters because a state maintained after withdrawal may present a different therapeutic target from one that requires continued drug exposure. This review examines how metabolic flux influences chromatin and how the resulting transcriptional changes shape cell states within the tumor microenvironment. We discuss clinical evidence for mutant IDH inhibition and consider investigational combinations that target metabolic and epigenetic regulators. We also examine how isotope tracing, single-cell and spatial multi-omics, and serial biomarker measurements can identify therapeutic dependencies, inform patient selection, and monitor emerging resistance.
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Fu, P., Chen, Y., Lin, Y., & Wang, L. (2026). Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities. Cancer Biome and Targeted Therapy, 252-278. https://doi.org/10.66505/cbtt.v1i4.56
Vancouver
Fu P, Chen Y, Lin Y, Wang L. Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities. Cancer Biome and Targeted Therapy. 2026:252-278. doi:10.66505/cbtt.v1i4.56
BibTeX
@article{Fu2026,
author = {Fu, Piaoting and Chen, Yiling and Lin, Yusheng and Wang, Lu},
title = {Metabolic-Epigenetic Reprogramming in Cancer: Cell-State Plasticity, Tumor Microenvironment, and Therapeutic Opportunities},
journal = {Cancer Biome and Targeted Therapy},
year = {2026},
pages = {252--278},
doi = {10.66505/cbtt.v1i4.56}
}
EUVIMED